An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project

Abstract

The goal of post-transplant immunosuppressive drug therapy is to prevent organ rejection while minimizing drug toxicities. In clinical practice, a multidrug approach is commonly used and involves drugs with different mechanisms of action, including calcineurin inhibitors (CNI) (tacrolimus or cyclosporine), antimetabolite (antimet) (mycophenolate or azathioprine), inhibitors of mechanistic target of rapamycin (mTOR) (sirolimus or everolimus), and/or steroids. Although evidence based on several randomized clinical trials is available, the optimal immunosuppressive therapy has not been established and may vary among organ transplant settings. To improve the knowledge on this topic, a multiregional research network to Compare the Effectiveness and Safety of Immunosuppressive drugs in Transplant patients (CESIT) has been created with the financial support of the Italian Medicines Agency. In this article, we describe the development of this network, the framework that was designed to perform observational studies, and we also give an overview of the preliminary results that we have obtained. A multi-database transplant cohort was enrolled using a common data model based on healthcare claims data of four Italian regions (Lombardy, Veneto, Lazio, and Sardinia). Analytical datasets were created using an open-source tool for distributed analysis. To link the National Transplant Information System to the regional transplant cohorts, a semi-deterministic record linkage procedure was performed. Overall, 6,914 transplant patients from 2009–19 were identified: 4,029 (58.3%) for kidney, 2,219 (32.1%) for liver, 434 (6.3%) for heart, and 215 (3.1%) for lung. As expected, demographic and clinical characteristics showed considerable variability among organ settings. Although the triple therapy in terms of CNI + antimet/mTOR + steroids was widely dispensed for all settings (63.7% for kidney, 33.5% for liver, 53.3% for heart, and 63.7% for lung), differences in the active agents involved were detected. The CESIT network represents a great opportunity to study several aspects related to the use, safety, and effectiveness of post-transplant maintenance immunosuppressive therapy in real practice.

Post-marketing active surveillance of Guillan Barré Syndrome following vaccination with anti-COVID-19 vaccines in persons aged ≥12 years in Italy: a multi-database self-controlled case series study

“…Over the last two years, TheShinISS framework has been employed in several large-scale observational studies exploring the association between some exposures and COVID-19 onset/prognosis as well as other drug and vaccinerelated research topics and is currently maintained by a collaborative research network. 1,2,[9][10][11][12][13] The relational scheme of the study databases as well as TheShinISS flow diagram is described in Figure 1. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint…”

Maintenance immunosuppressive therapy in liver transplantation: results from CESIT study, an Italian retrospective cohort study

“…Within this subset, there were 2,135 patients aged 18years or older, who had undergone transplantation for the rst time and survived for at least 30 days while using a CNI. Record linkage with the National Transplant Information System was successful, allowing identi cation of approximately 90% of patients using pseudoanonimous information (11). The 1,909 dead donor liver transplants were strati ed into 750 due to cirrhosis (39.3%) and 1,159 for HCC (60.7%).…”

“…Demographic and clinical characteristics of both donors and recipients, which were available nationwide, were linked through a semi-deterministic matching procedure (11). The study cohort was limited to patients residing in the considered regions who survived and had received at least one CNI immunosuppressive dispensation during the 30 days following their discharge (index period).…”

Postmarketing observational study on the safety of 2021/2022 and 2022/2023 influenza vaccination campaigns in Italy: TheShinISS-Vax|Flu study protocol

“…TheShinISS allows to carry out distributed analyses in multidatabase pharmacoepidemiological studies according to a CDM strategy which is study tailored 20. It has been already employed in large real-world studies with different epidemiological designs 8 9 21–25…”